Table 1 Clinical and disease characteristics

Median age, years (range) ^a

65 (27–90)

Male

57 (57%)

BRAF-mutation present

66 (66%)

LDH ^a

  < 1 ULN

57 (57%)

 1–2.5 ULN

27 (27%)

  > 2.5 ULN

9 (9%)

 Missing

7 (7%)

Time between metastatic melanoma diagnosis and brain metastases

 0 months

59 (59%)

 1 – 6 months

16 (16%)

 6 – 12 months

8 (8%)

 > 12 months

17 (17%)

Symptomatic brain metastases ^a

68 (68%)

Number of brain metastases ^a

 1

28 (28%)

 2–5

28 (28%)

 > 5

37 (37%)

 Leptomeningeal disease

7 (7%)

Interval between diagnosis brain metastases and death, months (range)

5.7 (0–42)

Disease status ^b

 Only intracranial progression

29 (29%)

 Only extracranial progression

2 (2%)

 Both

35 (35%)

 None

34 (34%)

Received systemic treatments before the last 3 months of life

Patients with a BRAF-mutation (n = 66)

 ICI

2 (3%)

 BRAF/MEK-inhibitors

23 (35%)

 ICI and BRAF/MEK-inhibitors

31 (47%)

 Chemotherapy

3 (5%)

Patients without a BRAF-mutation (n = 34)

 ICI

13 (38%)

 Chemotherapy

2 (6%)